Article Text

PDF

Randomised trial of corticosteroids in the treatment of tuberculous pleurisy.
  1. I Galarza,
  2. C Cañete,
  3. A Granados,
  4. R Estopà,
  5. F Manresa
  1. Servei de Pneumologia, Hospital Universitari de Bellvitge, Barcelona, Spain.

    Abstract

    BACKGROUND--Tuberculous pleurisy can result in pleural fibrosis, calcification and thickening. To prevent these complications, corticosteroids are frequently used in addition to antituberculous drugs; however, new therapeutic regimens can control the disease and minimise the sequelae, and there is no convincing evidence of the benefit of the use of corticosteroids as adjuvant therapy. METHODS--Patients received isoniazid 5 mg/kg and rifampicin 10 mg/kg daily for six months. Additionally, they were randomly assigned to a double blind treatment with either prednisone (1 mg/kg/day for 15 days and then tapering off) or placebo during the first month of treatment. Different clinical, radiological, and functional parameters were evaluated to assess the effect of corticosteroids. RESULTS--Fifty seven patients received prednisone and 60 placebo. At the end of the treatment the clinical outcome, the rate of reabsorption of the pleural fluid, the pleural sequelae, as well as lung capacity were similar in both groups. CONCLUSIONS--Corticosteroids do not influence the clinical outcome or the development of long term pleural sequelae in tuberculous pleurisy.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.